Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL IXEKIZUMAB MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL IXEKIZUMAB MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL IXEKIZUMAB MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 EPIDEMIOLOGY
11.1 INCIDENCE OF ALL BY GENDER
11.2 TREATMENT RATE
11.3 MORTALITY RATE
11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
11.5 PATIENT TREATMENT SUCCESS RATES
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.2.1 CLASS I
12.2.2 CLASS II
12.2.3 CLASS III
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13 PIPELINE ANALYSIS
13.1 CLINICAL TRIALS AND PHASE ANALYSIS
13.2 DRUG THERAPY PIPELINE
13.3 PHASE III CANDIDATES
13.4 PHASE II CANDIDATES
13.5 PHASE I CANDIDATES
13.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR IXEKIZUMAB MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR IXEKIZUMAB MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR IXEKIZUMAB MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR IXEKIZUMAB MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
TABLE 5 TOP ENTITIES BASED ON R&D GLANCE FOR IXEKIZUMAB MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
14 REIMBURSEMENT FRAMEWORK
15 OPPUTUNITY MAP ANALYSIS
16 VALUE CHAIN ANALYSIS
17 HEALTHCARE ECONOMY
17.1 HEALTHCARE EXPENDITURE
17.2 CAPITAL EXPENDITURE
17.3 CAPEX TRENDS
17.4 CAPEX ALLOCATION
17.5 FUNDING SOURCES
17.6 INDUSTRY BENCHMARKS
17.7 GDP RATION IN OVERALL GDP
17.8 HEALTHCARE SYSTEM STRUCTURE
17.9 GOVERNMENT POLICIES
17.1 ECONOMIC DEVELOPMENT
18 GLOBAL IXEKIZUMAB MARKET, BY PRODUCT TYPE
18.1 OVERVIEW
18.2 PREFILLED SYRINGES
18.2.1 CITRATE-FREE
18.2.2 WITH CITRATE
18.3 PREFILLED AUTOINJECTOR
18.3.1 CITRATE-FREE
18.3.2 WITH CITRATE
18.4 PEN INJECTOR
18.4.1 CITRATE-FREE
18.4.2 WITH CITRATE
18.5 OTHERS
19 GLOBAL IXEKIZUMAB MARKET, BY POPULATION TYPE
19.1 OVERVIEW
19.2 PEDIATRIC
19.3 ADULTS
19.4 GERIATRIC
20 GLOBAL IXEKIZUMAB MARKET, BY GENDER
20.1 OVERVIEW
20.2 MALE
20.3 FEMALE
21 GLOBAL IXEKIZUMAB MARKET, BY APPLICATION
21.1 OVERVIEW
21.2 PLAQUE PSORIASIS
21.3 PSORIATIC ARTHRITIS
21.4 ANKYLOSING SPONDYLITIS
21.5 SPONDYLOARTHRITIS
21.6 OTHERS
22 GLOBAL IXEKIZUMAB MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.3 SPECIALTY CLINICS
22.4 HOME HEALTHCARE
22.5 ACADEMIC AND RESEARCH INSTITUTE
22.6 OTHERS
23 GLOBAL IXEKIZUMAB MARKET, BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDER
23.3 RETAIL SALES
23.3.1 OFFLINE SALES
23.3.2 ONLINE SALES
23.4 OTHERS
24 GLOBAL IXEKIZUMAB MARKET, BY GEOGRAPHY
GLOBAL IXEKIZUMAB MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1 NORTH AMERICA
24.1.1 U.S.
24.1.2 CANADA
24.1.3 MEXICO
24.2 EUROPE
24.2.1 GERMANY
24.2.2 FRANCE
24.2.3 U.K.
24.2.4 ITALY
24.2.5 SPAIN
24.2.6 RUSSIA
24.2.7 TURKEY
24.2.8 NETHERLANDS
24.2.9 SWITZERLAND
24.2.10 REST OF EUROPE
24.3 ASIA-PACIFIC
24.3.1 JAPAN
24.3.2 CHINA
24.3.3 SOUTH KOREA
24.3.4 INDIA
24.3.5 AUSTRALIA
24.3.6 SINGAPORE
24.3.7 THAILAND
24.3.8 MALAYSIA
24.3.9 INDONESIA
24.3.10 PHILIPPINES
24.3.11 REST OF ASIA-PACIFIC
24.4 SOUTH AMERICA
24.4.1 BRAZIL
24.4.2 ARGENTINA
24.4.3 REST OF SOUTH AMERICA
24.5 MIDDLE EAST AND AFRICA
24.5.1 SOUTH AFRICA
24.5.2 SAUDI ARABIA
24.5.3 UAE
24.5.4 EGYPT
24.5.5 KUWAIT
24.5.6 ISRAEL
24.5.7 REST OF MIDDLE EAST AND AFRICA
24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL IXEKIZUMAB MARKET, SWOT AND DBMR ANALYSIS
26 GLOBAL IXEKIZUMAB MARKET, COMPANY LANDSCAPE
26.1 COMPANY SHARE ANALYSIS
26.2 MERGERS & ACQUISITIONS
26.3 NEW PRODUCT DEVELOPMENT & APPROVALS
26.4 EXPANSIONS
26.5 REGULATORY CHANGES
26.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
27 GLOBAL IXEKIZUMAB MARKET, COMPANY PROFILE
27.1 ELI LILLY AND COMPANY
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
